Evidence map›Paper›PMID 40176257›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025

Differences in Mortality Between Treatment-Naive and Treatment-Discontinuing Hospitalized Individuals With Advanced HIV Disease: A Comparative Retrospective Study From Mexico City.

Héctor Rivera-Villegas, Yanink Caro-Vega, André Trujillo-Gamboa, Álvaro Lopez-Iñiguez, Juan Sierra-Madero, Brenda Crabtree-Ramirez

Abstract readComparative Study
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Héctor Rivera-VillegasInfectious Diseases Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.ORCID 0009-0009-9735-3892
Yanink Caro-VegaInfectious Diseases Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
André Trujillo-GamboaInfectious Diseases Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.ORCID 0000-0001-6552-7928
Álvaro Lopez-IñiguezInfectious Diseases Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.ORCID 0000-0001-7128-2242
Juan Sierra-MaderoInfectious Diseases Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Brenda Crabtree-RamirezInfectious Diseases Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.ORCID 0000-0002-2587-1123

Funding

NIH HHS
6 · The paper itself

Abstract

backgroundAdvanced human immunodeficiency virus (HIV) disease is a major cause of morbidity and mortality in people with HIV in Latin America. It remains unclear whether mortality differs between people with advanced HIV who are treatment naive (TN) and those who have discontinued antiretroviral treatment (TD). We compared mortality differences between hospitalized TN and TD individuals with advanced HIV.

methodsAll adults hospitalized for advanced HIV disease (CD4 count <200 cells/μL or with AIDS-defining events) at a tertiary center in Mexico City between January 2015 and December 2022 were included. The primary outcome was 1-year mortality following hospitalization. Secondary outcomes were overall mortality and 30-day mortality.

resultsFour hundred seventy hospitalizations occurred in 299 adults with advanced HIV. Of these, 214 (72%) were TN at the time of admission, while 85 (28%) were TD. The median CD4 cell count was 76 cells/μL and AIDS-related infections accounted for most of the deaths. No differences were found between the groups regarding hospitalization days, CD4 cell count, or comorbidities. TD were more likely to have acquired HIV by sexual transmission (P = .009). One-year mortality was significantly higher in the TD group (24% vs 8%; P = .008). The overall mortality was also higher among TD individuals (P = .008). Multivariate analysis revealed an independent association between treatment discontinuation and mortality (hazard ratio, 2.08 [95% confidence interval, 1.14-3.78]).

conclusionsTreatment discontinuation is associated with worse clinical outcomes when compared to TN patients. Future research should focus on understanding the reasons for these findings to develop public health strategies to prevent disruption of the continuum of care.

Indexed as

Anti-HIV AgentsHIV InfectionsHospitalizationAdultCD4 Lymphocyte CountFemaleHumansMaleMexicoMiddle AgedRetrospective StudiesAnti-HIV Agentsadvanced HIV diseaseantiretroviral treatmentHIVmortalitytreatment-abandoned

Identifiers

PMID40176257
PMCPMC12598669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.